Mechanism of Action (MOA)

Epidyolex provides a different way to treat seizures vs. conventional anti-epileptic drugs (AEDs):1

 

  • Structurally distinct from other AEDs
  • Reduces neuronal hyper-excitability and inflammation through multiple MOAs
  • Does not exert its anticonvulsant effects through interaction with cannabinoid receptors

 

Epidyolex has a novel MOA, providing a valuable new approach to treating seizures. The precise mechanisms by which cannabidiol exerts its anticonvulsant effects in humans are unknown.1

 

Reduction of neuronal hyper-excitability via 3 main actions (theoretical):

1.
GPR55
Image
GPR55

Modulation of intracellular calcium via G-protein coupled receptor 55 (GPR55).
 

2.
TRPV-1
Image
TRPV-1

Modulation of intracellular calcium via transient receptor potential vanilloid 1 (TRPV-1).
 

3
ENT-1
Image
ENT-1

Modulation of adenosine-mediated signalling through inhibition of adenosine cellular uptake via the equilabrative nucleoside transporter 1 (ENT-1).

Discover the results

Epidyolex has been assessed in a large, controlled Phase III clinical trial programme within LGS and DS, including 714 patients.1

Efficacy

 

References

 

1. Epidyolex Summary of Product Characteristics (Date accessed: April 2021).